Skip to content

Study · Randomized controlled trial · n = 12 · 1997

17 results

Interaction of the growth hormone releasing peptide hexarelin with somatostatin.

Massoud AF, Hindmarsh PC, Brook CG

Clinical endocrinology1 Nov 1997Cited by 16 (Europe PMC)

PMID9425393 (opens in a new tab)DOI10.1046/j.1365-2265.1997.3121128.x (opens in a new tab)PepBankPUB-09425393
Publisher pagePubMedAsk about this study
Jump to 17 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study17

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanRandomized controlled trialMechanism

    In healthy men, hexarelin 0.5 microgram/kg given during a somatostatin infusion (50 micrograms/m2/h) produced a small GH response (peak 6.8 +/- 3.6 mU/l).

    In plain wordsIn healthy men, hexarelin given during a high-dose somatostatin infusion produced only a small growth hormone response.

    Peptide
    Hexarelin
    Outcome
    IncreaseGH response to hexarelin 0.5 microgram/kg during SS50 infusion
    Study

    n = 12

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.5 microgram/kg · intravenousAs given in this study (human).

    Measurements

    Peak GH
    6.8 mU/l
    hexarelin 0.5 microgram/kg during SS50

    Source sentences

    Summary
    The intravenous administration of hexarelin (0.5 microgram/kg) or GHRH-(1-29)-NH2 (0.5 microgram/kg) during an intravenous infusion of SS50 resulted in a small GH response (peak concentrations 6.8 +/- 3.6 mU/l and 2.4 +/- 0.5 mU/l, respectively)
    2 context sentences
    Summary · context
    Twelve healthy adult males (20.3-34.6 years) were studied.
    Summary · context
    Boluses of saline, hexarelin (1 microgram/kg), GHRH-(1-29)-NH2 (1 microgram/kg) or hexarelin plus GHRH-(1-29)-NH2 were administered intravenously 1 hour after the start of a 3-hour constant intravenous infusion of saline, SS(1-14) (20 micrograms/m2/h) (SS20) or SS(1-14) (50 micrograms/m2/h) (SS50).

Studies that did not test the peptide alone16

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 02HumanNot a test of Sermorelin aloneRandomized controlled trialActivity measurement

    In healthy adult men, a somatostatin infusion (SS20) significantly reduced the peak GH response to GHRH-(1-29)-NH2; GHRH was the test stimulus.

    In plain wordsIn healthy men, a somatostatin infusion lowered the peak growth hormone response to a GHRH test dose.

    Peptide
    Sermorelin
    Outcome
    DecreasePeak GH response to GHRH during somatostatin infusion
    Study

    n = 12

    Comparator
    Saline infusion
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    Infusion of SS20 resulted in a significant reduction in the peak GH response to hexarelin, GHRH-(1-29)-NH2 or hexarelin plus GHRH-(1-29)-NH2 (P < 0.05).
    2 context sentences
    Summary · context
    Twelve healthy adult males (20.3-34.6 years) were studied.
    Summary · context
    Boluses of saline, hexarelin (1 microgram/kg), GHRH-(1-29)-NH2 (1 microgram/kg) or hexarelin plus GHRH-(1-29)-NH2 were administered intravenously 1 hour after the start of a 3-hour constant intravenous infusion of saline, SS(1-14) (20 micrograms/m2/h) (SS20) or SS(1-14) (50 micrograms/m2/h) (SS50).

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  2. 03HumanNot a test of Sermorelin aloneRandomized controlled trialActivity measurement

    In healthy adult men, the higher somatostatin dose (SS50) did not significantly lower peak GH after GHRH-(1-29)-NH2 compared with SS20.

    In plain wordsIn healthy men, a higher somatostatin dose did not significantly lower the peak growth hormone response to GHRH further than the lower dose.

    Peptide
    Sermorelin
    Outcome
    No significant changePeak GH response to GHRH at higher somatostatin dose
    Study

    n = 12

    Comparator
    SS20 infusion
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    The peak serum GH concentrations following the intravenous administration of the two secretagogues, separately or in combination, were reduced further by the higher dose of SS50, but these were not significantly different from their respective peak serum GH concentrations obtained during the infusion of SS20.
    2 context sentences
    Summary · context
    Twelve healthy adult males (20.3-34.6 years) were studied.
    Summary · context
    Boluses of saline, hexarelin (1 microgram/kg), GHRH-(1-29)-NH2 (1 microgram/kg) or hexarelin plus GHRH-(1-29)-NH2 were administered intravenously 1 hour after the start of a 3-hour constant intravenous infusion of saline, SS(1-14) (20 micrograms/m2/h) (SS20) or SS(1-14) (50 micrograms/m2/h) (SS50).

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  3. 04HumanNot a test of Sermorelin aloneRandomized controlled trialActivity measurement

    In healthy adult men, hexarelin plus GHRH-(1-29)-NH2 still produced a large peak GH concentration despite a high-dose somatostatin infusion.

    In plain wordsIn healthy men, hexarelin plus GHRH still produced a large growth hormone peak during a high-dose somatostatin infusion.

    Peptide
    Sermorelin
    Outcome
    IncreasePeak GH after hexarelin plus GHRH during high-dose somatostatin
    Study

    n = 12

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    Peak serum GH
    52.6 mU/l
    hexarelin plus GHRH during SS50

    Source sentences

    Summary
    The peak serum GH concentration following the intravenous administration of hexarelin plus GHRH-(1-29)-NH2 remained large (52.6 +/- 7.2 mU/l; mean +/- SEM) despite the high dose of SS(1-14) (50 micrograms/m2/h).
    2 context sentences
    Summary · context
    Twelve healthy adult males (20.3-34.6 years) were studied.
    Summary · context
    Boluses of saline, hexarelin (1 microgram/kg), GHRH-(1-29)-NH2 (1 microgram/kg) or hexarelin plus GHRH-(1-29)-NH2 were administered intravenously 1 hour after the start of a 3-hour constant intravenous infusion of saline, SS(1-14) (20 micrograms/m2/h) (SS20) or SS(1-14) (50 micrograms/m2/h) (SS50).

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  4. 05HumanNot a test of Sermorelin aloneRandomized controlled trialActivity measurement

    In healthy adult men, withdrawal of the SS20 infusion at the time of GHRH-(1-29)-NH2 bolus did not significantly increase peak GH.

    In plain wordsIn healthy men, stopping somatostatin at the time of a GHRH dose did not significantly raise the growth hormone peak.

    Peptide
    Sermorelin
    Outcome
    No significant changePeak GH after somatostatin withdrawal with GHRH
    Study

    n = 12

    Comparator
    Saline infusion
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    Withdrawal of SS20 infusion at the time of intravenous bolus administration of hexarelin, but not GHRH-(1-29)-NH2 or hexarelin plus GHRH-(1-29)-NH2, resulted in a significant increase in peak serum GH concentration (P = 0.03).
    2 context sentences
    Summary · context
    Twelve healthy adult males (20.3-34.6 years) were studied.
    Summary · context
    Boluses of saline, hexarelin (1 microgram/kg), GHRH-(1-29)-NH2 (1 microgram/kg) or hexarelin plus GHRH-(1-29)-NH2 were administered intravenously 1 hour after the start of a 3-hour constant intravenous infusion of saline, SS(1-14) (20 micrograms/m2/h) (SS20) or SS(1-14) (50 micrograms/m2/h) (SS50).

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  5. 06HumanNot a test of Sermorelin aloneRandomized controlled trialActivity measurement

    In healthy adult men, a somatostatin infusion (SS20) significantly reduced the peak GH response to hexarelin plus GHRH-(1-29)-NH2; GHRH was a test stimulus together with hexarelin.

    In plain wordsIn healthy men, a somatostatin infusion lowered the peak growth hormone response to a test dose of hexarelin plus GHRH.

    Peptide
    Sermorelin
    Outcome
    DecreasePeak GH response to hexarelin plus GHRH during somatostatin infusion
    Study

    n = 12

    Comparator
    Saline infusion
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    Infusion of SS20 resulted in a significant reduction in the peak GH response to hexarelin, GHRH-(1-29)-NH2 or hexarelin plus GHRH-(1-29)-NH2 (P < 0.05).

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  6. 07HumanNot a test of Hexarelin aloneRandomized controlled trialMechanism

    In healthy men, a somatostatin infusion (20 micrograms/m2/h) significantly reduced the peak GH response to hexarelin.

    In plain wordsIn healthy men, a somatostatin infusion lowered the peak growth hormone response to hexarelin compared with saline.

    Peptide
    Hexarelin
    Outcome
    DecreasePeak GH response to hexarelin during SS20 infusion
    Study

    n = 12

    Comparator
    Saline infusion
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    Infusion of SS20 resulted in a significant reduction in the peak GH response to hexarelin, GHRH-(1-29)-NH2 or hexarelin plus GHRH-(1-29)-NH2 (P < 0.05).
    2 context sentences
    Summary · context
    Twelve healthy adult males (20.3-34.6 years) were studied.
    Summary · context
    Boluses of saline, hexarelin (1 microgram/kg), GHRH-(1-29)-NH2 (1 microgram/kg) or hexarelin plus GHRH-(1-29)-NH2 were administered intravenously 1 hour after the start of a 3-hour constant intravenous infusion of saline, SS(1-14) (20 micrograms/m2/h) (SS20) or SS(1-14) (50 micrograms/m2/h) (SS50).

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

  7. 08HumanNot a test of Hexarelin aloneRandomized controlled trialMechanism

    In healthy men, a somatostatin infusion (20 micrograms/m2/h) significantly reduced the peak GH response to hexarelin plus GHRH-(1-29)-NH2.

    In plain wordsIn healthy men, a somatostatin infusion lowered the peak growth hormone response to hexarelin given with GHRH compared with saline.

    Peptide
    Hexarelin
    Outcome
    DecreasePeak GH response to hexarelin plus GHRH during SS20 infusion
    Study

    n = 12

    Comparator
    Saline infusion
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    Infusion of SS20 resulted in a significant reduction in the peak GH response to hexarelin, GHRH-(1-29)-NH2 or hexarelin plus GHRH-(1-29)-NH2 (P < 0.05).
    2 context sentences
    Summary · context
    Twelve healthy adult males (20.3-34.6 years) were studied.
    Summary · context
    Boluses of saline, hexarelin (1 microgram/kg), GHRH-(1-29)-NH2 (1 microgram/kg) or hexarelin plus GHRH-(1-29)-NH2 were administered intravenously 1 hour after the start of a 3-hour constant intravenous infusion of saline, SS(1-14) (20 micrograms/m2/h) (SS20) or SS(1-14) (50 micrograms/m2/h) (SS50).

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

  8. 09HumanNot a test of Hexarelin aloneRandomized controlled trialMechanism

    In healthy men, peak GH after hexarelin or GHRH-(1-29)-NH2, alone or together, was lower with the higher somatostatin dose (50 micrograms/m2/h) but not significantly different from the lower dose.

    In plain wordsIn healthy men, a higher somatostatin dose did not lower the growth hormone response to hexarelin significantly more than the lower dose.

    Peptide
    Hexarelin
    Outcome
    No significant changePeak GH with SS50 versus SS20 infusion
    Study

    n = 12

    Comparator
    SS20 infusion
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    The peak serum GH concentrations following the intravenous administration of the two secretagogues, separately or in combination, were reduced further by the higher dose of SS50, but these were not significantly different from their respective peak serum GH concentrations obtained during the infusion of SS20.
    2 context sentences
    Summary · context
    Twelve healthy adult males (20.3-34.6 years) were studied.
    Summary · context
    Boluses of saline, hexarelin (1 microgram/kg), GHRH-(1-29)-NH2 (1 microgram/kg) or hexarelin plus GHRH-(1-29)-NH2 were administered intravenously 1 hour after the start of a 3-hour constant intravenous infusion of saline, SS(1-14) (20 micrograms/m2/h) (SS20) or SS(1-14) (50 micrograms/m2/h) (SS50).

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

  9. 10HumanNot a test of Hexarelin aloneRandomized controlled trialMechanism

    In healthy men, the peak GH concentration after hexarelin plus GHRH-(1-29)-NH2 remained large (52.6 mU/l) despite a high-dose somatostatin infusion.

    In plain wordsIn healthy men, hexarelin given with GHRH still produced a large growth hormone rise during a high-dose somatostatin infusion.

    Peptide
    Hexarelin
    Outcome
    Not applicablePeak GH with hexarelin plus GHRH during SS50 infusion
    Study

    n = 12

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    Peak GH
    52.6 mU/l
    hexarelin plus GHRH during SS50

    Source sentences

    Summary
    The peak serum GH concentration following the intravenous administration of hexarelin plus GHRH-(1-29)-NH2 remained large (52.6 +/- 7.2 mU/l; mean +/- SEM) despite the high dose of SS(1-14) (50 micrograms/m2/h).
    2 context sentences
    Summary · context
    Twelve healthy adult males (20.3-34.6 years) were studied.
    Summary · context
    Boluses of saline, hexarelin (1 microgram/kg), GHRH-(1-29)-NH2 (1 microgram/kg) or hexarelin plus GHRH-(1-29)-NH2 were administered intravenously 1 hour after the start of a 3-hour constant intravenous infusion of saline, SS(1-14) (20 micrograms/m2/h) (SS20) or SS(1-14) (50 micrograms/m2/h) (SS50).

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

  10. 11HumanNot a test of Hexarelin aloneRandomized controlled trialMechanism

    In healthy men, somatostatin did not affect the prolactin response to hexarelin.

    In plain wordsIn healthy men, somatostatin did not change the prolactin response to hexarelin.

    Peptide
    Hexarelin
    Outcome
    No significant changeProlactin response to hexarelin during somatostatin
    Study

    n = 12

    Outcome group
    Pituitary hormones · Endocrine and hormones

    Source sentences

    Summary
    SS(1-14) did not affect the PRL and cortisol response to hexarelin.
    2 context sentences
    Summary · context
    Twelve healthy adult males (20.3-34.6 years) were studied.
    Summary · context
    Boluses of saline, hexarelin (1 microgram/kg), GHRH-(1-29)-NH2 (1 microgram/kg) or hexarelin plus GHRH-(1-29)-NH2 were administered intravenously 1 hour after the start of a 3-hour constant intravenous infusion of saline, SS(1-14) (20 micrograms/m2/h) (SS20) or SS(1-14) (50 micrograms/m2/h) (SS50).

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

  11. 12HumanNot a test of Hexarelin aloneRandomized controlled trialMechanism

    In healthy men, somatostatin did not affect the cortisol response to hexarelin.

    In plain wordsIn healthy men, somatostatin did not change the cortisol response to hexarelin.

    Peptide
    Hexarelin
    Outcome
    No significant changeCortisol response to hexarelin during somatostatin
    Study

    n = 12

    Outcome group
    Pituitary hormones · Endocrine and hormones

    Source sentences

    Summary
    SS(1-14) did not affect the PRL and cortisol response to hexarelin.
    2 context sentences
    Summary · context
    Twelve healthy adult males (20.3-34.6 years) were studied.
    Summary · context
    Boluses of saline, hexarelin (1 microgram/kg), GHRH-(1-29)-NH2 (1 microgram/kg) or hexarelin plus GHRH-(1-29)-NH2 were administered intravenously 1 hour after the start of a 3-hour constant intravenous infusion of saline, SS(1-14) (20 micrograms/m2/h) (SS20) or SS(1-14) (50 micrograms/m2/h) (SS50).

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

  12. 13HumanNot a test of Hexarelin aloneRandomized controlled trialMechanism

    In healthy men, withdrawal of the somatostatin infusion at the time of hexarelin significantly increased the peak GH concentration (P = 0.03).

    In plain wordsIn healthy men, stopping a somatostatin infusion when hexarelin was given raised the peak growth hormone level.

    Peptide
    Hexarelin
    Outcome
    IncreasePeak GH response to hexarelin at SS20 withdrawal
    Study

    n = 12

    Comparator
    Saline infusion
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    Withdrawal of SS20 infusion at the time of intravenous bolus administration of hexarelin, but not GHRH-(1-29)-NH2 or hexarelin plus GHRH-(1-29)-NH2, resulted in a significant increase in peak serum GH concentration (P = 0.03).
    2 context sentences
    Summary · context
    Twelve healthy adult males (20.3-34.6 years) were studied.
    Summary · context
    Boluses of saline, hexarelin (1 microgram/kg), GHRH-(1-29)-NH2 (1 microgram/kg) or hexarelin plus GHRH-(1-29)-NH2 were administered intravenously 1 hour after the start of a 3-hour constant intravenous infusion of saline, SS(1-14) (20 micrograms/m2/h) (SS20) or SS(1-14) (50 micrograms/m2/h) (SS50).

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

  13. 14HumanNot a test of Hexarelin aloneRandomized controlled trialMechanism

    In healthy men, withdrawal of the somatostatin infusion at the time of hexarelin plus GHRH-(1-29)-NH2 did not significantly increase the peak GH concentration.

    In plain wordsIn healthy men, stopping somatostatin when hexarelin and GHRH were given together did not raise peak growth hormone significantly.

    Peptide
    Hexarelin
    Outcome
    No significant changePeak GH response to hexarelin plus GHRH at SS20 withdrawal
    Study

    n = 12

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    Withdrawal of SS20 infusion at the time of intravenous bolus administration of hexarelin, but not GHRH-(1-29)-NH2 or hexarelin plus GHRH-(1-29)-NH2, resulted in a significant increase in peak serum GH concentration (P = 0.03).
    2 context sentences
    Summary · context
    Twelve healthy adult males (20.3-34.6 years) were studied.
    Summary · context
    Boluses of saline, hexarelin (1 microgram/kg), GHRH-(1-29)-NH2 (1 microgram/kg) or hexarelin plus GHRH-(1-29)-NH2 were administered intravenously 1 hour after the start of a 3-hour constant intravenous infusion of saline, SS(1-14) (20 micrograms/m2/h) (SS20) or SS(1-14) (50 micrograms/m2/h) (SS50).

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

  14. 15HumanNot a test of Hexarelin aloneRandomized controlled trialMechanism

    In healthy men, later withdrawal of the somatostatin infusion was not followed by a rise in serum GH after hexarelin given during the infusion.

    In plain wordsIn healthy men, stopping the somatostatin infusion later did not cause a growth hormone rise after hexarelin given during the infusion.

    Peptide
    Hexarelin
    Outcome
    No significant changeGH rise after later SS50 withdrawal following hexarelin
    Study

    n = 12

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    but the later withdrawal of the infusion was not followed by a rise in serum GH concentrations
    2 context sentences
    Summary · context
    Twelve healthy adult males (20.3-34.6 years) were studied.
    Summary · context
    Boluses of saline, hexarelin (1 microgram/kg), GHRH-(1-29)-NH2 (1 microgram/kg) or hexarelin plus GHRH-(1-29)-NH2 were administered intravenously 1 hour after the start of a 3-hour constant intravenous infusion of saline, SS(1-14) (20 micrograms/m2/h) (SS20) or SS(1-14) (50 micrograms/m2/h) (SS50).

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

  15. 16HumanNot a test of Sermorelin aloneRandomized controlled trialActivity measurement

    In healthy adult men, GHRH-(1-29)-NH2 given during an SS50 infusion produced only a small GH response.

    In plain wordsIn healthy men, a low GHRH dose given during high-dose somatostatin produced only a small growth hormone response.

    Peptide
    Sermorelin
    Outcome
    IncreaseGH response to low-dose GHRH during high-dose somatostatin
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    Peak serum GH
    2.4 mU/l
    GHRH 0.5 microgram/kg during SS50

    Source sentences

    Summary
    The intravenous administration of hexarelin (0.5 microgram/kg) or GHRH-(1-29)-NH2 (0.5 microgram/kg) during an intravenous infusion of SS50 resulted in a small GH response (peak concentrations 6.8 +/- 3.6 mU/l and 2.4 +/- 0.5 mU/l, respectively)
    2 context sentences
    Summary · context
    Twelve healthy adult males (20.3-34.6 years) were studied.
    Summary · context
    Boluses of saline, hexarelin (1 microgram/kg), GHRH-(1-29)-NH2 (1 microgram/kg) or hexarelin plus GHRH-(1-29)-NH2 were administered intravenously 1 hour after the start of a 3-hour constant intravenous infusion of saline, SS(1-14) (20 micrograms/m2/h) (SS20) or SS(1-14) (50 micrograms/m2/h) (SS50).

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  16. 17HumanNot a test of Sermorelin aloneRandomized controlled trialActivity measurement

    In healthy adult men, withdrawal of the SS50 infusion after an earlier GHRH-(1-29)-NH2 dose was not followed by a rise in serum GH.

    In plain wordsIn healthy men, stopping high-dose somatostatin after an earlier low GHRH dose did not cause a rise in growth hormone.

    Peptide
    Sermorelin
    Outcome
    No significant changeGH rise after somatostatin withdrawal following low-dose GHRH
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    but the later withdrawal of the infusion was not followed by a rise in serum GH concentrations.
    2 context sentences
    Summary · context
    Twelve healthy adult males (20.3-34.6 years) were studied.
    Summary · context
    Boluses of saline, hexarelin (1 microgram/kg), GHRH-(1-29)-NH2 (1 microgram/kg) or hexarelin plus GHRH-(1-29)-NH2 were administered intravenously 1 hour after the start of a 3-hour constant intravenous infusion of saline, SS(1-14) (20 micrograms/m2/h) (SS20) or SS(1-14) (50 micrograms/m2/h) (SS50).

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 4 to 18Current

    28 Oct 2026, 02:02 UTC

    The same notice was added 15 times, first on 13 Oct 2026, 21:44 UTC. The status did not change between them.

    Study results updated

  2. Version 3

    13 Oct 2026, 16:31 UTC

    Study data updated · source update from Europe PMC

  3. Version 2

    9 Oct 2026, 19:08 UTC

    Study results updated

  4. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.